The treatment of BAPN with mice in carbon tetrachloride- (CCl4-) induced liver fibrosis facilitates fibrosis reversal after CCl4 withdrawal, supporting the concept of pharmacologic targeting of LOX pathway to inhibit liver fibrosis and promote its resolution [34]. The gene discussed is LOX; the disease is Hepatic fibrosis.